Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This prospective observational cohort study will evaluate different radiotherapy target volume delineation patterns in patients with locally advanced esophageal squamous cell carcinoma receiving radiotherapy combined with immunotherapy. In routine clinical practice, physicians may use different margins around the primary tumor and different approaches to regional lymph node irradiation. The study will not assign participants to a specific radiotherapy strategy. Instead, participants will receive treatment according to routine clinical practice, and the actual radiotherapy plans will be recorded and analyzed. The study will compare locoregional tumor control, recurrence patterns, survival, treatment-related toxicity, lymphocyte reduction, and completion of immunotherapy among patients receiving different target volume strategies. The main objective is to evaluate 2-year locoregional recurrence-free survival and to identify radiotherapy approaches that may achieve effective tumor control while reducing unnecessary radiation exposure and treatment-related toxicity.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-80 lat
- •Potwierdzony histologicznie rak płaskonabłonkowy przełyku
- •Zaawansowana choroba kwalifikująca się do radioterapii połączonej z immunoterapią
- •Planowana nowoczesna radioterapia precyzyjna (IMRT, VMAT, protonowa lub inna)
- •Wykonana tomografia komputerowa przed leczeniem
- •Sprawność fizyczna oceniana na 0-2 punkty (możliwość samoopieki)
- •Spodziewana długość życia co najmniej 6 miesięcy
- •Zdolność do podpisania świadomej zgody
✗ Disqualifies
- •Przerzuty do odległych narządów
- •Poprzednia radioterapia klatki piersiowej mogąca wpłynąć na obecne leczenie
- •Zapalenie płuc o charakterze śródmiąższowym lub ciężkie infekcje
- •Poważne choroby autoimmunologiczne niekontrolowane farmakologicznie
- •Brakujące dane uniemożliwiające określenie objętości obszaru do bestrahowania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- October 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
Trial contact
Xin Wang, PhD
Chao Xi Cao
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.